drugset
drugset / Trial / NCT00209950

A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia

NCT00209950 ↗

Phase 3 Completed 200 enrolled H. Lundbeck A/S
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and tolerability of gaboxadol in primary insomnia

Timeline

Start
2004-07
Primary completion
—
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Gaboxadol Unknown — —

Indications

insomnia